organoids services Market

The organoids services market is anticipated to grow from US$ 3.03 billion in 2023 and is projected to reach US$ 15.01 billion by 2031; it is expected to register a CAGR of 22.3% during 2023-2031.

Factors contributing to the organoids services market growth include the rising demand for novel drug screening services, and an upsurge in the popularity of customized medications. However, the dearth of skilled professionals and stringent safety regulations hamper the market growth.

Organoids are simple tissue-engineered cell-based in vitro models that recapitulate many aspects of the complex structure and function of the corresponding in vivo tissue. They can be dissected and interrogated for fundamental mechanistic studies on development, regeneration and repair in human tissues, and can also be used in diagnostics, disease modelling, drug discovery and personalized medicine.

North America dominates the organoids services market. Market players in the US are focusing on organic growth strategies to strengthen their foothold. In February 2023, Molecular Devices, LLC. and HUB Organoids (HUB) announced a strategic collaboration to continue the development of next-generation 3D biology technologies that drive step-change reduction in preclinical to clinical drug attrition. Further, increasing research and development activities, rising demand for tissue engineering and organ transplantation, and a high rate of organoid adoption are driving the organoid services market in the country. Organoids have the potential to overcome several previous limitations associated with biomedical research studies, with a high focus on making mechanistic insights on human development available for researchers, producing accurate models of human disease, and generating patient-matched tissue sources for regenerative medicine. Asia Pacific is anticipated to record the highest CAGR during 2023-2031.

Increasing Key Developments to Provide Market Opportunities in Future

The progress of the healthcare sector has led to a rise in the demand for organoids across the world. This increased demand contributes to new product developments, acquisitions, partnerships, product launches, and approvals on a global level. Major market players are involved in activities to ensure the innovation and development of efficient services and products. A few of the recent key developments are listed below:

? In June 2024, Molecular Devices, LLC. formally opened its purpose-built facility in Cardiff, UK. The multimillion-pound facility was designed to accommodate the exclusive bioprocess workflow and innovative bioreactor technology of the business, allowing for the large-scale, quality-controlled production of PDOs. Substantial amounts of repeatable PDOs that are 3D-ready are available as a custom service and are cryopreserved in a manner that is ready for analysis. Researchers can defrost, plate, and use these products as needed.

? In May 2024, InSphero, a biotech company, signed a partnership agreement with Genome Biologics, Frankfurt. In this partnership, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform provides accurate, scalable, and disease-specific organoid models for creating novel treatments, placing it at the forefront of heart disease research.

? In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications.

? In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to contribute to the continued development of next-generation 3D biology technologies that enable step-change reduction in preclinical to clinical drug attrition.

? In December 2022, Molecular Devices, LLC. acquired Cellesce Ltd. This acquisition focuses on producing large-scale PDOs for various purposes, including drug screening, through contract development and production services.

? In August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) signed an agreement. As a part of this agreement, STEMCELL's Contract Assay Services division began providing its tissue-derived organoids, such as lung, intestinal, and liver organoids, for pre-clinical toxicology screening and non-cancer drug development services to HUB. These services would facilitate the integration of organoids into preclinical testing programs by researchers and drug development organizations to aid in the faster and more economical launch of new therapies.

Such key developments, launches, and strategic collaborations among market players create ample opportunities for the organoid services market growth..

Application -Based Insights

By application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023-2031.

Source -Based Insights

Based on source, the organoids services market is divided into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2023. The pluripotent stem cells segment is anticipated to register a higher CAGR during the forecast period.

Organoids services Market: Competitive Landscape and Key Developments

Sino Biological Inc.; Eurofins Scientific SE; Molecular Devices, LLC.; InSphero; Cyprio; InnoSer; LABTOO; CUSABIO TECHNOLOGY LLC; Oncodesign Services; and HUB Organoids B.V. (Hubrecht Organoid Technology) are among the key companies operating in the organoids services market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the organoids services market report.